Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 7

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 7
---
 2021, and were subsequently separated on January 21, 2022, resulting in NorthView’s shares of common stock, its warrants and rights trading separately. NorthView is providing the accompanying proxy statement/prospectus and accompanying proxy card to NorthView’s stockholders in connection with the solicitation of proxies to be voted at the Special Meeting and at any adjournments of the Special Meeting. NorthView warrant holders and rights holders are not entitled to vote at the Special Meeting. Information about the Special Meeting, the Business Combination and other related business to be considered by NorthView’s stockholders at the Special Meeting is included in the accompanying proxy statement/prospectus. Whether or not you plan to attend the Special Meeting, all of NorthView’s stockholders are urged to read the accompanying proxy statement/prospectus, including the Annexes and other documents referred to therein, carefully and in their entirety. You should also carefully consider the risk factors described in “Risk Factors” beginning on page 27 of the accompanying proxy statement/prospectus. After careful consideration, the board of directors of NorthView has unanimously approved the Merger Agreement and the transactions contemplated thereby, including the Business Combination, and unanimously recommends that stockholders vote “FOR” the adoption of the Merger Agreement and approval of the transactions contemplated thereby, including the Business Combination, and “FOR” all other proposals presented to NorthView’s stockholders in the accompanying proxy statement / prospectus. When you consider the recommendation of these proposals by the board of directors of NorthView, you should keep in mind that NorthView’s directors, officers and initial stockholders have interests in the Business Combination that may differ from or conflict with your interests as a stockholder. For instance, the Sponsor will benefit from the completion of a business combination and may be incentivized to complete a business combination that is less favorable to stockholders of NorthView than liquidating NorthView. See “The Business Combination Proposal — Interests of Certain Persons in the Business Combination and Conflicts of Interest” in the accompanying proxy statement / prospectus for a further discussion of these considerations. Your vote is very important. Whether or not you plan to attend the Special Meeting, please vote as soon as possible by following the instructions in the accompanying proxy statement / prospectus to make sure that your shares are represented at the Special Meeting. If you hold your shares in “street name” through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your